

DNA Methyltransferase

DNMTs; DNA MTases

HDAC Inhibitor:
Vorinostat (SAHA)



HDAC (Histone deacetylase)

DNA methylation, defined by the addition of a methyl group to adenine or cytosine bases in DNA catalyzed by DNA methyltransferases (MTases), is one of the most studied post-replicative DNA modification mechanism in bacteria. The three forms of nucleotide methylation identified to date are: N6-methyladenine (m^6A), N4-methylcytosine (m^4C), and 5-methylcytosine (m^5C).

DNA methylation, one type of epigenetic modification, represses gene expression. DNA methylation is caused primarily by a family of DNA methyltransferases (DNMTs) including DNMT1, DNMT3a and DNMT3b. Conventionally, DNMT1 acts as the primary maintenance methyltransferase to keep the methylation of DNA that is already established at the genome, whereas DNMT3a and DNMT3b are classified as de novo methyltransferases to reversibly methylate unmethylated DNA. DNA methylation represses gene transcription through several mechanisms including physically blocking the binding of transcription factors and/or functioning as docking sites for transcriptional repressors/corepressors.

In epigenetic transcriptional regulation, which is important for embryonic development, DNA-methylation patterns are determined by de novo methylation by the DNA methyltransferases Dnmt3a and Dnmt3b in the embryo.

DNA methylation on the cytosine of CpG dinucleotides in gene promoter regions is associated with silencing gene expression. Of the DNA methyltransferases, only DNA methyltransferase 3a (DNMT3a) and 3b (DNMT3b) are capable of adding de novo CpG methylation marks and thus may dynamically regulate gene silencing.

DNA Methyltransferase Inhibitors & Modulators


5-Azacytidine

(Ladakamycin; 5-AzaC; Azacitidine)

Cat. No.: HY-10586

Bioactivity: 5-Azacytidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping **DNA methyltransferases**.

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
 100 mg, 200 mg, 500 mg




6-Methyl-5-azacytidine

Cat. No.: HY-111644

Bioactivity: 6-Methyl-5-azacytidine is a potent DNMT inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg




CM-579

Cat. No.: HY-117421

Bioactivity: CM-579 is a first-in-class reversible, dual inhibitor of **G9a** and **DNMT**, with **IC₅₀** values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells ^[1].

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg




CM-579 trihydrochloride

Cat. No.: HY-117421A

Bioactivity: CM-579 trihydrochloride is a first-in-class reversible, dual inhibitor of **G9a** and **DNMT**, with **IC₅₀** values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells ^[1].

Purity: 98.03%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 5 mg, 10 mg, 50 mg, 100 mg




DC-05

Cat. No.: HY-12746

Bioactivity: DC-05 is a DNA methyltransferase 1 (**DNMT1**) inhibitor, with an **IC₅₀** and a **K_d** of 10.3 μM and 1.09 μM, respectively.

Purity: 99.15%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 5 mg, 10 mg, 50 mg




DC_517

Cat. No.: HY-12747

Bioactivity: DC_517 is a DNA methyltransferase 1 (**DNMT1**) inhibitor, with an **IC₅₀** and a **K_d** of 1.7 μM and 0.91 μM, respectively.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 5 mg, 10 mg, 50 mg




Decitabine

(NSC 127716; 5-Aza-2'-deoxycytidine)

Cat. No.: HY-A0004

Bioactivity: Decitabine (NSC 127716) is a **DNA methyltransferase** inhibitor commonly used to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
 10 mg, 50 mg, 100 mg




Glucose-conjugated MGMT inhibitor

(O6BTG-C8-βGlu)

Cat. No.: HY-13057

Bioactivity: Glucose-conjugated MGMT inhibitor is a potent O⁶-methylguanine-DNA methyl-transferase (**MGMT**) inhibitor, with **IC₅₀**s of 32 nM in vitro (cell extracts) and 10 nM in HeLa S3 cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 5 mg, 10 mg, 50 mg




Guadecitabine

(SGI-110)

Cat. No.: HY-13542

Bioactivity: Guadecitabine (SGI-110) is a **DNA methyltransferases** (**DNMT**) inhibitor.

Purity: 98.00%
Clinical Data: Phase 3
Size: 5 mg, 10 mg



Guadecitabine sodium

(SGI-110 sodium; S-110 sodium)

Cat. No.: HY-15229

Bioactivity: Guadecitabine sodium (SGI-110 sodium; S-110 sodium) is a dinucleotide consisting of 5-Aza-CdR followed by a deoxyguanosine which shows to be an effective **DNA methylation inhibitor**.

Purity: 98.06%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 5 mg, 10 mg

